R&D | December 12, 2025
OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
The product will be marketed by Dr. Reddy's Laboratories Inc.
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Akero became a wholly owned subsidiary of Novo Nordisk
The study met its primary endpoint and all 11 secondary efficacy endpoints
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Subscribe To Our Newsletter & Stay Updated
